Free tool
Rare disease stocks
We cover 9 companies grouped under the Rare disease theme. The median market value in the group is $12.89B. Across the group, the median move over the past trading day is +0.67%. Price change over the past year runs from −21.6% to +43.1% across the middle 80 percent of the group, with a median of +1.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
9 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | $139.82B | Large cap | +41.64% | Nov 2, 2026 |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $112.52B | Large cap | +40.77% | Nov 2, 2026 |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $35.05B | Large cap | −46.60% | Oct 29, 2026 |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | $32.28B | Large cap | −10.21% | Oct 29, 2026 |
| 0JAV.L | Insmed Incorporated | $12.89B | Large cap | −7.52% | Oct 29, 2026 |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.57B | Large cap | +1.80% | Nov 10, 2026 |
| ABVX.PA | ABIVAX Société Anonyme | $10.21B | Large cap | +48.91% | Sep 21, 2026 |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +15.03% | Oct 26, 2026 |
| CAMX.ST | Camurus AB (publ) | $3.79B | Mid cap | −15.35% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.